



May 30, 2023

Pfizer Inc.
66 Hudson Blvd.
New York, NY 10011

Subject: Cease the sale of NICOTROL[®] Inhaler (nicotine inhalation system) once inventory is exhausted

Dear Health Care Provider:

The purpose of this letter is to inform you that as of approximately September 2023 Pfizer will no longer sell NICOTROL[®] Inhaler (nicotine inhalation system). This is the result of unavailability of an essential resin needed to produce the mouthpiece for the inhaler, and NOT due to any complaints or safety concerns. NICOTROL[®] Inhaler consists of a mouthpiece and a plastic cartridge delivering 4 mg of nicotine from a porous plug containing 10 mg nicotine.

The current supply of NICOTROL[®] Inhaler is expected to be available until September 2023.

NICOTROL[®] nasal spray will continue to be supplied by Pfizer. Pfizer cannot make recommendations regarding alternative treatments. Healthcare professionals should use their clinical expertise and judgement to determine an alternative treatment option for their patients.

NICOTROL[®] Inhaler helps you quit smoking by reducing your urge to smoke. The full Prescribing Information for NICOTROL[®] Inhaler can be found at:
https://cdn.pfizer.com/pfizercom/products/uspi_nicotrol_inhaler.pdf.

Reporting Adverse Events

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

For additional medical questions on NICOTROL, please contact Pfizer Medical Information 1-800-438-1985.

Sincerely,

Sveta Ferri, PharmD, CMD
US Medical Affairs
Pfizer Inc.

(c) 2023 Pfizer Inc. All rights reserved.